Qigong/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: A randomized controlled trial

Sleep disturbances and fatigue are common in prostate cancer patients undergoing radiotherapy. Prior research suggests mind-body techniques may improve these outcomes. We conducted a randomized-controlled trial of qigong/tai chi (QGTC) in men with prostate cancer undergoing radiotherapy.

Men with prostate cancer starting definitive radiation were randomized to one of three groups: (1) QGTC; (2) light exercise (LE); or (3) wait list control (WLC). Sleep disturbances (PSQI) and fatigue (BFI) were assessed at baseline, mid-radiotherapy (T2), during the last week of radiotherapy (T3) and at 1 (T4) and 3 months (T5) after the end of radiotherapy. Patients in the QGTC and LE groups attended three 40-minute classes per week throughout radiotherapy.

Ninety patients were randomized to the three groups (QGTC = 26; LE = 26; WLC = 24). QGTC group reported longer sleep duration at mid-XRT (QGTC = 7.01 hours; LE = 6.42; WL = 6.50; p = 0.05) but this difference did not persist over time. There were no group differences in other domains of sleep or fatigue. Exploratory analyses conducted to examine the effect of health-related QOL (EPIC and AUA score) on sleep and fatigue showed significant correlations across multiple domains.

QGTC during radiation for prostate cancer resulted in superior sleep duration midway through radiation, but this effect was not durable and there were no differences in other domains of sleep or fatigue. Exploratory analysis demonstrated that both sleep and fatigue were highly correlated with prostate cancer related physical symptoms. Future mind-body intervention studies should incorporate multi-modal therapy focused on improving physical symptoms in this population.

Psycho-oncology. 2016 Aug 22 [Epub ahead of print]

Jennifer McQuade, Sarah Prinsloo, David Z Chang, Amy Spelman, Qi Wei, Karen Basen-Engquist, Carol Harrison, Zonghao Zhang, Debra Kuban, Andrew Lee, Lorenzo Cohen

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA., Department of Palliative Care, Rehabilitation Medicine, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Virginia Oncology Associates and Department of Medicine, Eastern Virginia Medical School, Newport News, VA, USA., Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., School of Physical Education and Sports, Soochow University, Suzhou, China., Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Radiation Oncology, Texas Oncology, Irving, Texas, USA.